Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Opdivo Projected to Grow 38% to 155 Billion Yen, but Ono Chief Sees No Re-Pricing
Ono Pharmaceutical is expecting its PD-1 inhibitor Opdivo (nivolumab) to grow 37.8% to 155 billion yen in the year through March 2023, but President Gyo Sagara says it is unlikely that the drug would be caught by re-pricing rules even…
To read the full story
Related Article
- Ono’s Sales Rise 7% on Overseas Growth of Qinlock, Romvimza
October 31, 2025
- Ono’s Profits Slide Over 60% as Deciphera Buyout Costs Swell
May 9, 2025
- Ono’s H1 Revenue Falters 7% after Opdivo Price Cuts
November 1, 2024
- Ono Crosses 500 Billion Yen in FY2023 Sales, Forxiga Drives 9th Year of Growth
May 10, 2024
- Ono Posts Record High H1 Earnings for 6th Consecutive Year Driven by Opdivo
November 2, 2023
- Ono Scores 12.5% Rise in Q1 Revenue on Opdivo, Forxiga
August 1, 2023
- Opdivo’s Japan Patent to Expire in 2031, Ono to Cover LOE with New Launches: Chief
May 11, 2023
- Ono Notches Two-Digit Growth in FY2022; Opdivo en Route to 150 Billion Yen Mark
May 11, 2023
- Ono’s 9-Month Revenue Climbs 25% on Robust Opdivo and Forxiga Sales
February 1, 2023
- Ono’s April-September Sales Zoom 24.5% on Bullish Opdivo and Forxiga
November 1, 2022
- Ono Logs Two-Digit Growth in Q1 Earnings on Opdivo
August 2, 2022
- Ono Nets 16.8% Sales Growth on Opdivo, Forxiga; 400 Billion-Plus Yen Eyed for FY2022
May 12, 2022
BUSINESS
- Gilead Names Andrew Hexter as Japan President
April 2, 2026
- Santen Sets May Launch Date for Upneeq as Non-Reimbursed Drug
April 2, 2026
- Shionogi Completes ViiV Stake Increase to 21.7%
April 2, 2026
- Kei Kaneda Becomes President of Moderna Japan
April 2, 2026
- Human Judgment Still Key in the AI Era, Pharma Leaders Tell New Recruits
April 2, 2026
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…